IMU Biosciences Raises Over $53 Million to Expand Operations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Source: Yahoo Finance
- Successful Fundraising: IMU Biosciences has successfully raised over $53 million (£40 million) in its latest financing round, co-led by IQ Capital and Molten Ventures, with proceeds aimed at supporting operational expansion and clinical platform development, reflecting strong investor confidence in its immune data technology.
- Immune Dataset Scale: IMU has built the world's largest immune dataset, scaling to over 25,000 individuals, and by combining high-fidelity multi-omic analysis with proprietary machine learning, it can measure over 100 million immune data points from a simple blood sample, significantly enhancing the precision of disease diagnosis and treatment.
- Advancing Clinical Programs: The funding will support IMU's clinical programs, including Stem Cell Transplant and Solid Organ Transplant initiatives, as well as the MANIFEST research consortium, which investigates patient responses to cancer immunotherapies, further advancing the development of precision medicine.
- Strategic Vision: CEO John Baker stated that this fundraising will enable the company to expand operations and develop its platform, aiming to fundamentally change how diseases are understood, diagnosed, and treated, thereby improving health outcomes for patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GROW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GROW
About GROW
U.S. Global Investors, Inc. is an investment adviser. The Company offers exchange traded funds (ETFs) in addition to mutual funds. The Company, with principal operations located in San Antonio, Texas, manages two business segments: Investment Management Services and Corporate Investments. Investment Management Services, through which the Company offers, to U.S. Global Investors Funds (USGIF) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors. Corporate Investments, through which the Company invests for its own account. In particular, the Company is known for its expertise in gold mining and exploration, natural resources, and airlines. It provides investment advisory services and administrative services to mutual funds. Its wholly owned subsidiaries include U.S. Global Investors (Bermuda) Limited, U.S. Global Investors (Canada) Limited and U.S. Global Indices, LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Global Investors Restates Earnings Report
- Restatement Impact: U.S. Global Investors has restated its earnings per share (EPS) for the three and nine months ended March 31, 2026, with basic and diluted EPS adjusted from $0.23 to $0.21 and from $0.27 to $0.26 respectively, demonstrating the company's commitment to accurate financial reporting.
- Strong Financial Performance: Despite the restatement, the company reported a net income of $2.7 million for Q3 2026, a significant improvement from a loss in the same quarter last year, indicating robust financial health in the market.
- Significant Revenue Growth: Total operating revenues for the third quarter reached $2.8 million, reflecting a 10% increase over the previous quarter and a 31% increase compared to the same quarter in fiscal year 2025, showcasing the company's strong performance in gold and natural resources strategies.
- Assets Under Management: The average assets under management (AUM) during the quarter stood at $1.6 billion, highlighting the company's investment management capabilities and market confidence, further enhancing shareholder yield commitments.
See More
IMU Biosciences Raises Over $53 Million to Expand Operations
- Successful Fundraising: IMU Biosciences has successfully raised over $53 million (£40 million) in its latest financing round, co-led by IQ Capital and Molten Ventures, with proceeds aimed at supporting operational expansion and clinical platform development, reflecting strong investor confidence in its immune data technology.
- Immune Dataset Scale: IMU has built the world's largest immune dataset, scaling to over 25,000 individuals, and by combining high-fidelity multi-omic analysis with proprietary machine learning, it can measure over 100 million immune data points from a simple blood sample, significantly enhancing the precision of disease diagnosis and treatment.
- Advancing Clinical Programs: The funding will support IMU's clinical programs, including Stem Cell Transplant and Solid Organ Transplant initiatives, as well as the MANIFEST research consortium, which investigates patient responses to cancer immunotherapies, further advancing the development of precision medicine.
- Strategic Vision: CEO John Baker stated that this fundraising will enable the company to expand operations and develop its platform, aiming to fundamentally change how diseases are understood, diagnosed, and treated, thereby improving health outcomes for patients.
See More
U.S. Global Investors Restates Earnings Report
- Reason for Restatement: U.S. Global Investors is restating its earnings per share (EPS) for the three and nine months ended March 31, 2026, due to a miscalculation that understated the weighted average shares, resulting in an overstatement of EPS by $0.02 for three months and $0.01 for nine months.
- Scope of Impact: The restatement only affects the EPS calculations, with net income of $2.7 million and other financial metrics remaining unchanged, indicating that the company's fundamentals are still strong.
- Commitment to Shareholder Returns: Over the past five years, the company has repurchased approximately 2.7 million shares, representing a reduction of over 20%, and continues to return capital to shareholders through monthly dividends and buyback programs, demonstrating a long-term commitment to investors.
- Growth in Assets Under Management: As of March 31, 2026, the average assets under management reached $1.6 billion, the highest level in nearly two years, and despite the correction in per-share figures, the narrative of profitability remains robust.
See More
U.S. Global Investors Q3 2026 Earnings Call Insights
- Shareholder Return Strategy: CEO Frank Holmes stated that the company strategically buys back stock using an algorithm on flat or down days, successfully preserving cash for future growth, with a total shareholder yield of 9.96%.
- Financial Performance Highlights: CFO Lisa Callicotte reported that average assets under management were $1.63 billion for Q3 2026, with operating revenues of $2.8 million and quarterly net income of $2.6 million, translating to earnings per share of $0.23, indicating a return to profitability.
- Market Dynamics and ETF Trends: Holmes emphasized that active ETFs attracted $500 billion in net inflows in 2025, with over 80% of new ETF launches being active, highlighting the strategic importance of the company's positioning in this sector.
- Tax Benefits and Cost Control: Callicotte noted that the company recognized a tax benefit of $844,000 this quarter, primarily from discrete tax adjustments, while operating expenses decreased to $2.7 million, demonstrating effective cost management.
See More
U.S. Global Investors Reports Q3 Earnings with Strong Revenue Growth
- Earnings Highlights: U.S. Global Investors (GROW) reported Q3 2026 results with a GAAP EPS of $0.23 and revenue of $2.76 million, reflecting a robust 31.4% year-over-year growth, indicating strong market performance.
- Asset Management Growth: As of March 31, 2026, the average assets under management (AAUM) reached $1.6 billion, the highest since June 2024, showcasing increased investor confidence in the company's offerings.
- Dividend Announcement: The Board approved a monthly dividend of $0.0075 per share starting in April 2026 through June 2026, demonstrating a commitment to shareholder returns and enhancing investor confidence.
- Payment Schedule: Dividend payments are scheduled for May 26 and June 29, with record dates of May 11 and June 15, ensuring timely returns for shareholders and further increasing the company's attractiveness.
See More
U.S. Global Investors Reports Strong Q2 Results with Revenue Growth
- Revenue Growth: U.S. Global Investors reported Q2 revenue of $2.5 million, reflecting significant growth compared to the same period last year, which is expected to further boost investor confidence in the firm.
- Increase in AUM: Total assets under management (AUM) reached approximately $1.5 billion at quarter-end, representing a 12% increase from the previous quarter and a 5% increase year-over-year, indicating the company's sustained competitive strength in the market.
- Expense Reduction: The company reduced expenses by $172,000 compared to the same quarter last year, demonstrating positive progress in cost control, which enhances overall profitability.
- Improved Pre-Tax Income: The company reported pre-tax income of $535,000, a significant turnaround from a pre-tax loss of $116,000 in the same quarter last year, showcasing improved operational efficiency and recovery in profitability.
See More
U.S. Global Investors Restates Earnings Report
- Restatement Impact: U.S. Global Investors has restated its earnings per share (EPS) for the three and nine months ended March 31, 2026, with basic and diluted EPS adjusted from $0.23 to $0.21 and from $0.27 to $0.26 respectively, demonstrating the company's commitment to accurate financial reporting.
- Strong Financial Performance: Despite the restatement, the company reported a net income of $2.7 million for Q3 2026, a significant improvement from a loss in the same quarter last year, indicating robust financial health in the market.
- Significant Revenue Growth: Total operating revenues for the third quarter reached $2.8 million, reflecting a 10% increase over the previous quarter and a 31% increase compared to the same quarter in fiscal year 2025, showcasing the company's strong performance in gold and natural resources strategies.
- Assets Under Management: The average assets under management (AUM) during the quarter stood at $1.6 billion, highlighting the company's investment management capabilities and market confidence, further enhancing shareholder yield commitments.
See More
IMU Biosciences Raises Over $53 Million to Expand Operations
- Successful Fundraising: IMU Biosciences has successfully raised over $53 million (£40 million) in its latest financing round, co-led by IQ Capital and Molten Ventures, with proceeds aimed at supporting operational expansion and clinical platform development, reflecting strong investor confidence in its immune data technology.
- Immune Dataset Scale: IMU has built the world's largest immune dataset, scaling to over 25,000 individuals, and by combining high-fidelity multi-omic analysis with proprietary machine learning, it can measure over 100 million immune data points from a simple blood sample, significantly enhancing the precision of disease diagnosis and treatment.
- Advancing Clinical Programs: The funding will support IMU's clinical programs, including Stem Cell Transplant and Solid Organ Transplant initiatives, as well as the MANIFEST research consortium, which investigates patient responses to cancer immunotherapies, further advancing the development of precision medicine.
- Strategic Vision: CEO John Baker stated that this fundraising will enable the company to expand operations and develop its platform, aiming to fundamentally change how diseases are understood, diagnosed, and treated, thereby improving health outcomes for patients.
See More
U.S. Global Investors Restates Earnings Report
- Reason for Restatement: U.S. Global Investors is restating its earnings per share (EPS) for the three and nine months ended March 31, 2026, due to a miscalculation that understated the weighted average shares, resulting in an overstatement of EPS by $0.02 for three months and $0.01 for nine months.
- Scope of Impact: The restatement only affects the EPS calculations, with net income of $2.7 million and other financial metrics remaining unchanged, indicating that the company's fundamentals are still strong.
- Commitment to Shareholder Returns: Over the past five years, the company has repurchased approximately 2.7 million shares, representing a reduction of over 20%, and continues to return capital to shareholders through monthly dividends and buyback programs, demonstrating a long-term commitment to investors.
- Growth in Assets Under Management: As of March 31, 2026, the average assets under management reached $1.6 billion, the highest level in nearly two years, and despite the correction in per-share figures, the narrative of profitability remains robust.
See More
U.S. Global Investors Q3 2026 Earnings Call Insights
- Shareholder Return Strategy: CEO Frank Holmes stated that the company strategically buys back stock using an algorithm on flat or down days, successfully preserving cash for future growth, with a total shareholder yield of 9.96%.
- Financial Performance Highlights: CFO Lisa Callicotte reported that average assets under management were $1.63 billion for Q3 2026, with operating revenues of $2.8 million and quarterly net income of $2.6 million, translating to earnings per share of $0.23, indicating a return to profitability.
- Market Dynamics and ETF Trends: Holmes emphasized that active ETFs attracted $500 billion in net inflows in 2025, with over 80% of new ETF launches being active, highlighting the strategic importance of the company's positioning in this sector.
- Tax Benefits and Cost Control: Callicotte noted that the company recognized a tax benefit of $844,000 this quarter, primarily from discrete tax adjustments, while operating expenses decreased to $2.7 million, demonstrating effective cost management.
See More
U.S. Global Investors Reports Q3 Earnings with Strong Revenue Growth
- Earnings Highlights: U.S. Global Investors (GROW) reported Q3 2026 results with a GAAP EPS of $0.23 and revenue of $2.76 million, reflecting a robust 31.4% year-over-year growth, indicating strong market performance.
- Asset Management Growth: As of March 31, 2026, the average assets under management (AAUM) reached $1.6 billion, the highest since June 2024, showcasing increased investor confidence in the company's offerings.
- Dividend Announcement: The Board approved a monthly dividend of $0.0075 per share starting in April 2026 through June 2026, demonstrating a commitment to shareholder returns and enhancing investor confidence.
- Payment Schedule: Dividend payments are scheduled for May 26 and June 29, with record dates of May 11 and June 15, ensuring timely returns for shareholders and further increasing the company's attractiveness.
See More
U.S. Global Investors Reports Strong Q2 Results with Revenue Growth
- Revenue Growth: U.S. Global Investors reported Q2 revenue of $2.5 million, reflecting significant growth compared to the same period last year, which is expected to further boost investor confidence in the firm.
- Increase in AUM: Total assets under management (AUM) reached approximately $1.5 billion at quarter-end, representing a 12% increase from the previous quarter and a 5% increase year-over-year, indicating the company's sustained competitive strength in the market.
- Expense Reduction: The company reduced expenses by $172,000 compared to the same quarter last year, demonstrating positive progress in cost control, which enhances overall profitability.
- Improved Pre-Tax Income: The company reported pre-tax income of $535,000, a significant turnaround from a pre-tax loss of $116,000 in the same quarter last year, showcasing improved operational efficiency and recovery in profitability.
See More
